drugset / Trial / NCT02262663

Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan

NCT02262663

Phase 1 Completed 70 enrolled Bayer
RandomizedParallel-groupQuadruple-blind

Summary

This is a study in healthy women of reproductive age to investigate the pharmacodynamics (mainly ovarian activity), pharmacokinetics and safety of vilaprisan after daily oral administration of 4 different doses over 84 days, using a randomized, parallel-group, multicenter design.

Timeline

Start
2014-10
Primary completion
2015-09
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 0.5 mg Oral
Subject Vilaprisan Other / unclassified 1 mg Oral
Subject Vilaprisan Other / unclassified 2 mg Oral
Subject Vilaprisan Other / unclassified 4 mg Oral

Indications

No indication recorded.